2026 is going to be an exciting year for the GLP-1 space – you know it and I know it.

Long dominated by the likes of Eli Lilly and Novo Nordisk, several other drugmakers are expected to challenge for market share. More drugmakers are coming in for a slice of that increasingly lucrative pie.

We can never get enough conversation around GLP-1s, which is why we’re capping 2025 with one more interview about this powerful class of drugs.

​Katie Chlada, managing director at M+C Saatchi North America, joins us as our final podcast guest of the year.

A self-described “GLP-1 evangelist” and “nerd,” Katie spoke with managing editor Jack O’Brien about what the future holds for these drugs, the access and affordability obstacles facing patients and how medical marketers can better communicate about these medications.

And for our Trends segment, we have an interview from our recent AI Deciphered conference with Ian Cohen, head of creative and content, global communications at Ford Motor Company.

Check us out at: mmm-online.com

Follow us:

YouTube: @MMM-online

TikTok: @MMMnews

Instagram: @MMMnewsonline

Twitter/X: @MMMnews

LinkedIn: MM+M

To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Music: “Deep Reflection” by DP and Triple Scoop Music.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Millions of Americans know what it’s like to live with inflammatory skin conditions – including Stella McDermott, the daughter of actress and author Tori Spelling.

Earlier this fall, Tori spoke with People magazine about her own episodic eczema flare-ups in adulthood, how Stella has experienced bullying related to her chronic eczema and how the pair have become more confident while embarking on their respective skincare journeys.

By publicly sharing their patient stories, Tori and Stella have formed the bedrock of Arcutis Biotherapeutics’ recently-launched Free to Be Me skincare campaign.

The effort elevates their experiences while also drawing attention to how Arcutis’ Zoryve – a once-daily, nonsteroidal topical – offers patients with inflammatory skin conditions another effective treatment option.

This week, pharma editor Lecia Bushak speaks with Arcutis CEO Frank Watanabe about the drugmaker’s partnership with Spelling, how the effort aims to raise awareness of inflammatory skin conditions and what the drugmaker’s growth strategy looks like heading into 2026.

And for our Trends segment, we’re joined by editor-in-chief Jameson Fleming to discuss the medical marketing implications from Omnicom’s takeover of IPG.

Check us out at: mmm-online.com

Follow us:

YouTube: @MMM-online

TikTok: @MMMnews

Instagram: @MMMnewsonline

Twitter/X: @MMMnews

LinkedIn: MM+M

To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Music: “Deep Reflection” by DP and Triple Scoop Music.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.